Final Results
Cizzle Biotechnology Holdings plc has published its Annual Report and Financial Statements for the year ended 31 December 2025, detailing its progress as a UK-based diagnostics developer of early cancer tests. The report is available via a provided link and will be accessible on the National Storage Mechanism and the Company's website. The company is focused on its CIZ1B biomarker, a non-invasive blood test for early lung cancer detection, and has entered into commercial royalty-bearing arrangements and collaborations.
Select text to share a quote on X · sign in to keep highlights & notes in your CIZ notes
Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, announces the publication of the Company's Annual Report and Financial Statements for the year ended 31 December 2025 (the "Annual Report").
The Annual Report is available via http://www.rns-pdf.londonstockexchange.com/rns/4787C_1-2026-4-29.pdf and will shortly be available to view on the on the National Storage Mechanism (NSM) and the Company's website: https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.